Accueil   Diary - News   All news CarThera announces enrollment of first melanoma patient in new clinical trial for SonoCloud technology

CarThera announces enrollment of first melanoma patient in new clinical trial for SonoCloud technology

 

SoniMel study aims to demonstrate safety of SonoCloud procedure
for patients with brain metastases from melanoma

 

Paris, France, June 8, 2020 – CarThera, a French company that designs and develops innovative ultrasound-based medical devices to treat brain disorders, today announces that the first patient has been enrolled and treated in a clinical trial evaluating the safety of using its SonoCloud ® technology in combination with checkpoint inhibitors for the treatment of brain metastases from melanoma (NCT04021420).

 

CarThera has demonstrated the feasibility of its SonoCloud approach in previous glioblastoma studies and actively supports institutional research.1 The SoniMel study – sponsored by Greater Paris University Hospitals and funded by the French National Cancer Institute – aims to demonstrate the safety of the procedure for patients with brain metastases from melanoma and to determine the optimal dose for further developments in this indication. The study is expected to finish in mid-2021.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree